Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVI 7537

Next Previous
Search
Drug Profile

AVI 7537

Alternative Names: AVI-7537

Latest Information Update: 28 Dec 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action RNA interference; Viral RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ebola virus infections

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(In volunteers) in USA (IV, Infusion)
  • 11 Nov 2014 Phase-I clinical trials in Ebola virus infections (In volunteers) in USA (IV)
  • 23 Jan 2013 Sarepta Therapeutics terminates phase I trial (prior to enrolment for convenience of US government due to funding constraints) in Ebola virus infections (in volunteers) in USA (NCT01593072)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top